Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

SQZ Biotechnologies brings in $15.7mm through Series B round

Executive Summary

SQZ Biotechnologies Co. (cell engineering technologies) raised $15.7mm in a Series B round co-led by NanoDimension and Polaris Partners (also a Series A investor), with 24 other existing and new investors also participating, according to the Form D. Since its 2013 inception, the company has raised $22mm. In December 2015, it began a partnership worth up to $500mm with Roche to treat several types of cancer through the modulation of B-cells, using SQZ's CellSqueeze cell membrane disruption platform.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies